Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 4/20 | 0.44 |
| ▸ | HTR7 | P34969 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL915159 | 0.82 | VCP (0.43) | VCPKMT2AMEN1ALDH1A1CYP2C9 | |
| SCHEMBL915160 | 0.82 | VCP (0.43) | VCPKMT2AMEN1ALDH1A1CYP2C9 | |
| SCHEMBL916229 | 0.80 | TDP1 (0.50) | VCPKMT2AMEN1ALDH1A1GAA | |
| SCHEMBL594858 | 0.75 | ALDH1A1 (0.67) | KMT2AMEN1ALDH1A1CYP2C9GAA | |
| SCHEMBL594857 | 0.75 | ALDH1A1 (0.67) | KMT2AMEN1ALDH1A1CYP2C9GAA | |
| SCHEMBL4983066 | 0.75 | KMT2A (0.46) | KMT2AMEN1ALDH1A1CYP2C9PKM | |
| SCHEMBL915177 | 0.75 | ALDH1A1 (0.43) | VCPKMT2AMEN1ALDH1A1CYP2C9 | |
| SCHEMBL915175 | 0.75 | ALDH1A1 (0.43) | VCPKMT2AMEN1ALDH1A1CYP2C9 | |
| SCHEMBL4654803 | 0.74 | ALDH1A1 (0.65) | KMT2AMEN1ALDH1A1CYP2C9GAA | |
| SCHEMBL2146869 | 0.74 | KMT2A (0.51) | KMT2AMEN1ALDH1A1CYP2C9PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372881-B2 | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | XENOPORT, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20110009483-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009483-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE | ACMSD, APEH, CPS1 | VCP 3099/4885HTR7 1013/4885KMT2A 1530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.